Abstract
A novel series of thieno[3,2-d]pyrimidine derivatives were synthesised and their inhibitory effects against diacylglycerol acyltransferase 1 (DGAT-1) were assessed. cis-Isomer 17a showed potent and selective inhibitory activity against DGAT-1 in SF9 cells. In addition, 17a had an acceptable pharmacokinetic profile and accumulated mainly in the small intestine and liver. Oral administration of 17a led to a significant reduction in plasma triacylglycerol level during an oral lipid tolerance test (OLTT) in murine and canine models. Taken together, 17a is a high-quality candidate that deserves further investigation.
Keywords:
DGAT-1; obesity; small molecules; thienopyrimidine; type 2 diabetes.
MeSH terms
-
Animals
-
Diacylglycerol O-Acyltransferase / antagonists & inhibitors*
-
Diacylglycerol O-Acyltransferase / metabolism
-
Dogs
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Male
-
Mice
-
Mice, Inbred ICR
-
Molecular Structure
-
Pyrimidines / chemical synthesis
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology*
-
Structure-Activity Relationship
Substances
-
Enzyme Inhibitors
-
Pyrimidines
-
thienopyrimidine
-
DGAT1 protein, human
-
Diacylglycerol O-Acyltransferase
Grants and funding
This research was supported by the Advanced Research Centre Programme (2015R1A5 A1008958) funded by the Korean Government.